Работы, на которые ссылается эта работа

Работ: 163

Работа: Translational research of new developments in targeted therapy of colorectal cancer

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram +3
Статья2018Цитирований: 34
ABI
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi, Steven O’Day, David F. McDermott +26
Статья2010Цитирований: 9
ABI
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Robert D. Schreiber, Lloyd J. Old, Mark J. Smyth
Обзорная статья2011Цитирований: 5
ABI
Comprehensive review of targeted therapy for colorectal cancer
Yuanhong Xie, Yingxuan Chen, Jing‐Yuan Fang
Обзорная статья2020Цитирований: 5
ABI
Без названия
ДругоеЦитирований: 4
ABI
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Herbert I. Hurwitz, Louis Fehrenbacher, William Novotny +12
Статья2004Цитирований: 4
ABI
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Jérôme Galon, Anne Costes, Fátima Sánchez‐Cabo +13
Статья2006Цитирований: 4
ABI
Diagnosis and Treatment of Metastatic Colorectal Cancer
Leah H. Biller, Deborah Schrag
Обзорная статья2021Цитирований: 4
ABI
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Rakesh K. Jain
Обзорная статья2001Цитирований: 3
ABI
Molecular targeted therapy: Treating cancer with specificity
Yeuan Ting Lee, Yi Jer Tan, Chern Ein Oon
Обзорная статья2018Цитирований: 3
ABI
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Julie R. Brahmer, Karen L. Reckamp, Paul Baas +22
Статья2015Цитирований: 3
ABI
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey, Eric Van Cutsem, Alberto Sobrero +17
Статья2012Цитирований: 3
ABI
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
Michael J. Overman, Sara Lonardi, Ka Yeung Mark Wong +17
Статья2018Цитирований: 3
ABI
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Lei Zhong, Yueshan Li, Liang Xiong +8
Обзорная статья2021Цитирований: 3
ABI
Strategies for enzyme/prodrug cancer therapy.
Guo Xu, Howard L. McLeod
Статья2001Цитирований: 2
ABI
An overview of targeted cancer therapy
V. Vijaya Padma
Статья2015Цитирований: 2
ABI
Без названия
ДругоеЦитирований: 2
ABI
Use of Real‐World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design
Simon Dagenais, Leo Russo, Ann Madsen +2
Обзорная статья2021Цитирований: 2
ABI
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Rakesh K. Jain
Обзорная статья2005Цитирований: 2
ABI
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
Bruno Sangro, Carlos Gómez-Martín, Manuel de la Mata +11
Статья2013Цитирований: 2
ABI
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?
Giuseppe Bronte, Nicola Silvestris, Marta Castiglia +10
Обзорная статья2015Цитирований: 2
ABI
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
Caroline Robert, Georgina V. Long, Benjamin Brady +25
Статья2014Цитирований: 2
ABI
Phase II Study of the Anti-Cytotoxic T-Lymphocyte–Associated Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal Cancer
Ki Y. Chung, Ira Gore, Lawrence Fong +8
Статья2010Цитирований: 2
ABI
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Leonard B. Saltz, John V. Cox, Charles D. Blanke +9
Статья2000Цитирований: 2
ABI
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman, Ray McDermott, Joseph L. Leach +13
Статья2017Цитирований: 2
ABI